Skip to content

Michael J. Cunningham

3 papers in the library · 139 citations · publishing 2022-2024

Papers

Sort Most recent Most cited

Structural pharmacology and therapeutic potential of 5-methoxytryptamines.

Nature June 1, 2024 Audrey L Warren, David Lankri, Michael J. Cunningham et al. 74 citations

Psychedelic substances such as lysergic acid diethylamide (LSD) and psilocybin show potential for the treatment of various neuropsychiatric disorders1-3. These compounds are thought to mediate their hallucinogenic and therapeutic effects through the serotonin (5-hydroxytryptamine (5-HT)) receptor 5-HT2A (ref. 4). However, 5-HT1A also plays a part in the behavioural effects of tryptamine...

Pharmacological Mechanism of the Non-hallucinogenic 5-HT2A Agonist Ariadne and Analogs

ACS Chemical Neuroscience December 15, 2022 Michael J. Cunningham, Hailey A. Bock, Inis C. Serrano et al. 65 citations

Ariadne is a non-hallucinogenic analog in the phenylalkylamine chemical class of psychedelics that is closely related to an established synthetic hallucinogen, 2,5-dimethoxy-4-methyl-amphetamine (DOM), differing only by one methylene group in the α-position to the amine. Ariadne has been tested in humans including clinical trials at Bristol-Myers Company that indicate a lack of hallucinogenic...